Sanjay Popat/royalmarsden.nhs.uk
Dec 11, 2024, 14:33
Sanjay Popat: Becotarug and osimertinib cohort expansion in treatment-naive EGFR mutation
Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared a post on X:
“Becotarug (JMT101) IgG EGFR AB and osimertinib cohort expansion in treatment-naive EGFR mutation 19/21. N=33 ORR 78.8% PFS 20.8mo, AEs per EGFR type. Phase 2/3 trials planned. Hmm…”
More posts featuring Sanjay Popat.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32